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Recent papers from Mahata et al. and Bereshchenko et al. reveal how steroids steer immune
responses by tipping T helper (Th) subset balances and activities. Pregnenolone produced by
Th2 cells mediates immunosuppressive responses, and glucocorticoids stimulate regulatory
T cell development via the induction of GILZ expression.Steroids are hormones that are involved
in diverse physiological functions ranging
from regulation of metabolism, behavior,
and fertility to inflammation and immune
control. The different forms of steroids
(progesterone, mineralocorticoids, glu-
cocorticoids [GCs], androgens, and es-
trogens) all (1) form by a synthesis
pathway that starts with conversion of
cholesterol into pregnenolone, (2) are
to some degree anti-inflammatory and
immunosuppressive, (3) interact with a
specific nuclear receptor, and (4) can act
on distant tissues. Steroid synthesis has
historically been associated with organs
such as the testes, ovaries, and the
adrenal glands, but recent evidence
points to synthesis in other organs. GC
synthesis, for example, has been de-
tected in the gut, lungs, and skin (Noti
et al., 2009). Although low in concentra-
tion in these organs, these steroids may
be important for local control of biological
processes.
We know that infections and other
challenges to homeostasis are controlled
by our innate (fast and poorly specific)
and adaptive (slow and highly specific)
immune systems. The specificity of the
adaptive immune response is guided in
part by the action of T helper (Th) cells
that differentiate into a subset of effectors
(Th1, Th2, Th17, memory Th, and regula-
tory T [Treg] cells) on the basis of the
nature of the antigen and external stimuli.
Two recent Cell Reports papers reveal
groundbreaking details about how ste-
roids regulate the differentiation of Th
cell subsets, in particular Th2 cells that
regulate host immunity to helminths and
Treg cells that protect against excessive
immune responses.938 Cell Reports 7, May 22, 2014 ª2014 TheIn a paper published in this issue of
Cell Reports, Mahata et al. (2014) per-
formed single-cell RNA sequencing on
Th subsets and discovered that Th2
cells express the enzyme Cyp11a1, which
is essential for transforming cholesterol
into the steroid pregnenolone. This ex-
pression is clearly associated with a
block in Th cell proliferation and immuno-
modulating activities of these Th2 cells,
such as B cell immunoglobulin class
switching, suggesting that steroids pro-
duced by the Th2 cells themselves may
be novel immunomodulators. These re-
sults suggest that ‘‘lymphosteroids’’ may
act not only on other cell types such as
innate immune cells and structural cells
but also on the local production of and/or
further metabolism of steroids in these
cells. This type of cascading effect could
potentially lead to a generalized immu-
nosuppression. Additional study of lym-
phosteroid regulation, as well as their
impact on thewhole organismversus local
tissues, would likely also reveal if/how
they cause or exacerbate side effects,
such as those seen with GC treatment of
chronic inflammation (Dejager et al.,
2014). For instance, howwould local stim-
ulation or inhibition of Cyp11a1 impact
mouse models of Th2-mediated colitis
(Noti et al., 2009) or other inflammatory
conditions? Moreover, lymphosteroids
may play a role in escape from immune
suppression of the hypothalamic-pitui-
tary-adrenal axis that can occur during
sepsis and/or may allow affected individ-
uals to overcome reduced steroid pro-
duction in cases of adrenal insufficiency
or necrosis (Cohen and Venkatesh, 2010).
GCs are predominantly produced by
the adrenal cortex and are potent modu-Authorslators of inflammation and immunosup-
pression. GCs bind and activate the GC
receptor (GR), which functions in the nu-
cleus by two binding mechanisms: (1) as
a homodimer to promoters of a wide
range of genes, including anti-inflam-
matory genes (such as Tsc22d3, which
codes for the anti-inflammatory protein
GC-induced leucine zipper [GILZ]), or (2)
as a monomer to inflammatory transcrip-
tion factors, such as nuclear factor kB
(NFkB), AP-1, and IRF3, thereby diminish-
ing their transcriptional activities.
A second new mechanism by which
steroids (GCs, in this case) regulate Th
subsets is reported by Bereshchenko
et al. (2014), who describe the molecular
mechanism through which GILZ strongly
impacts Treg cell proliferation. The bind-
ing of GILZ to NFkB is considered to
be its major immunosuppressive activity.
Now, Bereshchenko et al. (2014) show
that GILZ binds to SMAD2, an essential
signal transducing molecule in the path-
way initiated by Treg-cell-activating cyto-
kine TGF-b. The authors find that GILZ
leads to SMAD2 phosphorylation and
consequent optimal induction of Foxp3,
a typical marker of Treg cells that is
responsible for Treg cell proliferation.
The authors provide a physiological con-
text for the role of GILZ in peripheral
Treg (pTreg) cell proliferation by exam-
ining the effects of GILZ overexpression
or knockout in a mouse model of inflam-
matory bowel disease. However, given
that the depletion of GILZ does not
completely impair the production of
pTreg cells, it might be interesting to
study which additional mechanisms con-
tribute to their development and whether
GCs are involved in these processes.
The results also raise the question of
whether enhanced Treg cell proliferation
is involved in the reported protective
effects of GILZ in other inflammatory
settings, such as endotoxemia (Pinheiro
et al., 2013) and arthritis (Beaulieu et al.,
2010; Ngo et al., 2013). The reported
strong anti-inflammatory role of GILZ
undermines the dogma that GR-dimer-
dependent actions are dispensable for
the beneficial immunosuppressive func-
tion of GCs (Vandevyver et al., 2013).
Therefore, the current development of
dissociated compounds that act only on
GR-monomer-dependent actions might
not mimic all anti-inflammatory actions
of GR because they don’t induce GILZ.
On the basis of the findings of Mahata
et al. (2014) and the reported local
production of GCs in intestinal epithelial
cells (Noti et al., 2009), it is worth inves-
tigating whether local GC production
in Treg cells also occurs and whether
such locally produced GCs contribute
to the production of GILZ and to the
development of pTreg cells. In addition,
additional research will likely elucidate
whether inflammatory stimuli enhancethese effects, given that proinflammatory
cytokines can promote local steroidogen-
esis by directly inducing steroidogenic
enzymes in epithelial cells (Noti et al.,
2010). On the other hand, it is not clear
yet how the immunosuppressive effects
of the lymphosteroids described by Ma-
hata et al. (2014) are exerted. It is impor-
tant to investigate which steroid nuclear
receptor is engaged during immunosup-
pression and whether nongenomic or
genomic actions are involved. In the latter
case, it would be interesting to study
whether steroid-induced anti-inflamma-
tory effectors such as GILZ are involved.
These insights may lead to new thera-
peutic strategies that enhance local
steroid or GILZ production to stimulate
restoration of immune homeostasis or
improve immune tolerance while poten-
tially avoiding side effects that are
typically associated with steroid-based
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